Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated MCRC Clinical Study
Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated MCRC Clinical Study
– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth –
— 在RAS突變的mCRC中，新的臨床前發現表明onvansertib抑制腫瘤適應缺氧的能力，從而顯著降低腫瘤的血管形成和生長 —
– Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC –
— 在 1b/2 期試驗中，bev naiève 患者的臨床療效信號增強與隨機 ONSEMBLE 試驗的結果一致，該試驗在二線 mCRC 中提供了兩個獨立的數據集，驗證了我們在RAS突變的一線 mCRC 中評估onvansertib與chemo/bev聯合使用的策略 —
Therapeutic areas outside of RAS-mutated mCRC
Ras突變的 mCRC 以外的治療區域
– In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status –
— 在Ras-Wild型mCRC中，onvansertib作爲單一藥物在臨床前模型中表現出抗腫瘤活性，並與西妥昔單抗聯合使用，這突顯了mCRC中的onvansertib活性可以與RAS突變狀態無關 —
– In SCLC and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors –
— 在小細胞肺癌和卵巢癌中，可靠的臨床前數據凸顯了onvansertib在多種腫瘤聯合治療中的活性 —